SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...

First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...

BOSTON, MA—For patients with atrial fibrillation who are undergoing left atrial appendage occlusion (LAAO), the Amplatzer Amulet (Abbott) and the first-generation Watchman 2.5 (Boston Scientific) ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Rates of patency and device-related thrombus were ...

First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. BOSTON — At 3 years, the Amplatzer Amulet device ...

ORLANDO – November 6, 2021 – SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency ...

Abbott Laboratories received FDA approval for its Amplatzer Amulet left atrial appendage occluder to treat people with atrial fibrillation who are at risk of ischemic stroke about a month earlier than ...

Heart doctors at OhioHealth Mansfield Hospital this month celebrated their 500th procedure to help reduce the risk of stroke in patients with atrial fibrillation. The milestone left atrial appendage ...

The Amplatzer Amulet (Abbott) and first-generation Watchman 2.5 (Boston Scientific) devices provide relatively comparable results out to 3 years after left atrial appendage occlusion (LAAO), longer ...

DETROIT (June 30, 2022) – Findings of a Henry Ford Health study published in the Journal of American Heart Association from researchers in the Center for Structural Heart Disease (Division of ...

TCT 1285: Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): 5-year follow-up of a randomized controlled trial Receive the the latest news, research, and ...